GLP1R and obesity disorder: Canadian clinical guidelines recommend pharmacological treatments for obesity, specifically GLP-1 receptor agonists such as liraglutide and semaglutide, in addition to behavioral and nutritional interventions for adults with a BMI of 30 kg/m2 or ≥27 kg/m2 with complications related to adiposity [37].